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OBJECTIVE — The purpose of this study was to examine the predictors of intensiﬁcation of
antihyperglycemic therapy in patients with type 2 diabetes; its impact on A1C, body weight,
symptoms of anxiety/depression, and health status; and patient characteristics associated with
improvement in A1C.
RESEARCH DESIGN AND METHODS — We analyzed survey, medical record, and
health plan administrative data collected in Translating Research into Action for Diabetes
(TRIAD). We examined patients who were using diet/exercise or oral antihyperglycemic medi-
cations at baseline, had A1C 7.2%, and stayed with the same therapy or intensiﬁed therapy
(initiated or increased the number of classes of oral antihyperglycemic medications or began
insulin) over 18 months.
RESULTS — Of 1,093 patients, 520 intensiﬁed therapy with oral medications or insulin.
Patientsintensifyingtherapywereaged5812years,haddiabetesdurationof119years,and
had A1C of 9.1  1.5%. Younger age and higher A1C were associated with therapy intensiﬁca-
tion. Compared with patients who did not intensify therapy, those who intensiﬁed therapy
experienceda0.49%reductioninA1C(P0.0001),a3-poundincreaseinweight(P0.003),
and no change in anxiety/depression (P  0.5) or health status (P  0.2). Among those who
intensiﬁed therapy, improvement in A1C was associated with higher baseline A1C, older age,
black race/ethnicity, lower income, and more physician visits.
CONCLUSIONS — Treatment intensiﬁcation improved glycemic control with no wors-
ening of anxiety/depression or health status, especially in elderly, lower-income, and mi-
nority patients with type 2 diabetes. Interventions are needed to overcome clinical inertia
when patients might beneﬁt from treatment intensiﬁcation and improved glycemic control.
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O
ver the past decade, the number of
therapies available for the manage-
mentoftype2diabeteshasincreased
dramatically. Much of the evidence dem-
onstrating the efﬁcacy of these therapies
has come from randomized, controlled,
clinical trials (1,2). The effectiveness of
these therapies in real-world clinical set-
tings has not been studied as thoroughly.
Clinical inertia, deﬁned as the failure
of health care providers to appropriately
intensify medical management (3), and
patient nonadherence, deﬁned as the fail-
ure of patients to initiate or continue
physician-recommended changes in
management, contribute to suboptimal
glycemic control (4–6). A previous study
of patients with poorly controlled diabe-
tes showed that older patients and those
ofnonwhiterace/ethnicitywerelesslikely
to have their treatment intensiﬁed than
younger, white individuals (7). Physi-
cians cite concerns about hypoglycemia,
weight gain, and patient preferences as
reasons for not intensifying therapy, and
patients often express concerns about in-
jections and the negative impact on qual-
ity of life as reasons for not intensifying
therapy. Ideally, diabetes treatment regi-
mens should be individually designed to
prevent complications and comorbidities
while respecting patient preferences and
optimizing quality of life.
The current analyses were designed
to assess the impact of changes in antihy-
perglycemic therapies on health out-
comesinmanagedcarepatientswithtype
2 diabetes. Speciﬁcally, we assessed the
predictors of intensiﬁcation of antihyper-
glycemic therapy, its impact on A1C,
body weight, symptoms of anxiety/
depression, and health status, and patient
characteristics associated with improve-
ment in A1C.
RESEARCH DESIGN AND
METHODS— Translating Research
intoActionforDiabetes(TRIAD)hasbeen
described in detail elsewhere (8). In brief,
TRIADstudiedarandomsampleofadults
aged 18 years with diabetes from 10
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ing 180,000 patients with diabetes.
Institutional review boards at each partic-
ipating site approved the study. All par-
ticipants provided informed consent.
In 2000–2001, a baseline survey was
administered (response rate 69%), and in
2002–2003, a follow-up survey was ad-
ministered (response rate 80%), either by
computer-assisted telephone interview or
in writing by mail. Medical records and
health plan administrative data for each
participant were reviewed at each time
point. We studied patients who had sur-
vey and medical record data at both base-
line and follow-up, had type 2 diabetes
(excluding those with age at diagnosis
30 years and treated with insulin only),
and were using diet/exercise alone or in
combination with oral antihyperglycemic
medications at baseline (n  3,828). We
further limited the population to patients
whohadtwoA1Cvaluesreportedintheir
medicalrecords180daysapartandhad
pharmacy usage as evidenced by at least
one claim for a prescription in the admin-
istrative data at baseline and one at fol-
low-up (n  2,886). Characteristics of
our study population were similar to
those of the entire TRIAD population
(data not shown). For the purpose of
these analyses, we considered the thresh-
old for optimal control to be the popula-
tion median A1C of 7.2%. Anyone with
A1C above this threshold was considered
to have “suboptimally controlled” diabe-
tes. We excluded 1,513 individuals who
had A1C 7.2% at baseline (n  1,373)
(Fig. 1). Age, sex, race/ethnicity, educa-
tional level, income, duration of diabetes,
BMI, Charlson index, and provider type
were ascertained from the patient survey
andhad15%missingdata.Weimputed
missing values for these variables using
the transcan function in S-PLUS (edition
6.1, Insightful, Seattle, WA). A sensitivity
analysis that excluded patients with miss-
ing data yielded results similar to those
presented (data not shown).
We used health plan administrative
data to identify what type(s) of antihyper-
glycemicmedication(s),ifany,thepatient
possessed on the date of baseline and fol-
low-up A1C testing. We classiﬁed a per-
son as taking insulin if he or she ﬁlled a
prescription for insulin both 0–3 months
before the test date and 3–6 months be-
fore the test date. We created variables at
baseline and follow-up to indicate the
typeofantihyperglycemictherapythepa-
tient was using: diet/exercise only; one,
two, three, or four classes of oral antihy-
perglycemic medications (secretogogues,
biguanides, thiazolidinediones, or -glu-
cosidase inhibitors); or insulin. We then
created a variable with three categories
(deintensify, stay the same, and intensify)
representing the change in therapy from
baselinetofollow-up.Deintensifywasde-
ﬁned as decreasing the number of classes
of oral antihyperglycemic medications
and/or stopping insulin between baseline
and follow-up (n  280). Stay the same
was deﬁned as remaining with diet/
exercise therapy only, the same number
of classes of oral antihyperglycemic med-
ications, or insulin at baseline and fol-
low-up (n  573). Intensify was deﬁned
as initiating or increasing the number of
classes of oral antihyperglycemic medica-
tions or beginning insulin (n  520). In-
dividuals who deintensiﬁed therapy from
baseline to follow-up were excluded from
this analysis (Fig. 1).
We conducted bivariate analyses to
compare patient characteristics among
those who intensiﬁed therapy and those
who stayed with the same therapy using t
tests for continuous variables and 
2 tests
for categorical variables. We also com-
pared those who intensiﬁed with oral
medication(s) and those who intensiﬁed
withinsulin.Weusedmultivariablelogis-
tic regression analyses, which accounted
for clustering of patients at the health
plan/provider group level to examine fac-
tors associated with intensiﬁcation of
therapy. We included the following
variables measured at baseline: age, sex,
race/ethnicity, income, education, A1C,
Charlson index, management of patient’s
diabetes by an endocrinologist, and pro-
vider communication. We also included
the number of visits to the primary care
physician (PCP), whether the patient re-
ported being hospitalized, the develop-
ment of complications (self-reported
retinopathy, nephropathy, neuropathy,
and cardiovascular disease), and the oc-
currence of symptoms of hyperglycemia
(dry mouth, excessive thirst, and noctu-
ria) between baseline and follow-up.
The outcomes of intensiﬁcation of
therapy were measured with the fol-
low-up survey and medical record re-
view. A1C was obtained from medical
records; weight, anxiety/depression, and
health status were obtained from self-
report; and hypoglycemia was obtained
from administrative claims data. Anxiety/
depression and health status were mea-
sured with the EQ-5D, a generic measure
of health status with three levels repre-
sentingnoproblems,someproblems,and
extreme problems. For anxiety/
depression, we created a dichotomous
variable to indicate whether symptoms 1)
stayed at none or some or got better or 2)
got worse or remained extreme. We also
recategorized health status into a dichot-
Figure 1—Study population.
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follow-up measurement was better or
the same as (greater than or equal to) the
baseline measurement or whether the fol-
low-up measurement was worse than
(lessthan)thebaselinemeasurement.Hy-
poglycemia was deﬁned by the presence
of at least one inpatient or outpatient
claim in the administrative data (D-9-CM
codes 250.8 [diabetes with other speci-
ﬁed manifestations], 251.0 [hypoglyce-
mic coma], 251.1 [other speciﬁed
hypoglycemia], and 251.2 [hypoglyce-
mia, unspeciﬁed]). We used t tests to
compare values for continuous outcomes
(A1Candweight)and
2teststocompare
categorical outcomes (anxiety/depres-
sion, health status, and hypoglycemia).
We performed multivariable regres-
sion analyses for the population that
intensiﬁed therapy with either oral medi-
cationsorinsulintoexaminepatientchar-
acteristics associated with improvement
in A1C. The outcome for this regression
model was the difference in A1C calcu-
lated as the follow-up A1C minus the
baseline A1C. A negative regression coef-
ﬁcient represents a decrease or improve-
ment in A1C over time and a positive
regression coefﬁcient indicates an in-
crease or worsening in A1C over time.
The multivariate model included the
baseline measurement of A1C, age, sex,
race/ethnicity, education, income, BMI,
Charlsonindex,andmanagementofthepa-
tient’s diabetes by an endocrinologist. We
also adjusted for the number of visits to the
PCP from baseline to follow-up, whether
the patient was hospitalized between base-
line and follow-up, new onset of complica-
tionsfrombaselinetofollow-up,andhealth
plan/providergroupclustering.Allanalyses
were performed with SAS (version 9.1.3 SP
4; SAS Institute, Cary, NC).
RESULTS— For the 1,093 patients
withtype2diabetesandA1C7.2%,the
mean baseline A1C was 8.9% and the
range was 7.3–15.6%. During the 18-
month follow-up period, 520 of the1,093
(48%) patients with suboptimally con-
trolled type 2 diabetes intensiﬁed antihy-
perglycemictherapybyaddingeithernew
oralantihyperglycemicmedicationsorin-
sulin. The mean number of new oral an-
tihyperglycemic medication classes
added was 1.2 (range 1–3). Patients in-
tensifying therapy were on average 58 
12 years of age, with diabetes duration of
11  9 years and baseline A1C of 9.1 
1.5% (Table 1). Those who intensiﬁed
therapy were younger and heavier, had
higher A1C, had more visits to their PCP,
and were more likely to have developed
nephropathy between baseline and fol-
low-up (Table 1). In adjusted analyses,
only younger age (odds ratio [OR] 0.98
[95% CI 0.97–1.00]) and higher baseline
A1C (1.21 [1.09–1.34]) predicted ther-
apy intensiﬁcation.
In subanalyses comparing character-
isticsofindividualswhointensiﬁedtherapy
with insulin versus oral antihyperglyce-
mic medication(s), we found that those
whointensiﬁedtherapywithinsulinwere
morelikelytobewomen,tobeheavier,to
have longer duration of diabetes, and to
have higher A1C (Table 1). They were
also more likely to be “sicker” as evi-
denced by a higher Charlson index, more
visits to the PCP, more hospitalizations,
and more frequent development of com-
plications between baseline and fol-
low-up (Table 1). In adjusted analyses,
only higher baseline A1C (OR 1.26 [95%
CI 1.01–1.58]), higher Charlson index
(1.17 [1.03–1.32]), and greater number
offollow-upvisitstothePCP(1.08[1.01–
1.16]) predicted intensiﬁcation of ther-
apy with insulin.
Inunadjustedanalyses,thosewhoin-
tensiﬁed therapy had a 0.48% reduction
in A1C, a 3-pound weight gain, and no
signiﬁcant change in anxiety/depression
orhealthstatuscomparedwiththosewho
remained with the same therapy (Table 2).
Ofthosewhointensiﬁedtherapy,4%hadat
least one hypoglycemic event compared
with 3% of those who remained with the
sametherapy,and21%achievedA1C7%
comparedwith17%ofthosewhoremained
with the same therapy (Table 2).
In subanalyses of those who intensi-
ﬁed therapy with insulin versus oral anti-
hyperglycemic medication(s), we found
that those who intensiﬁed therapy with
insulin had a 0.37% greater reduction in
A1C and no signiﬁcant change in weight,
anxiety/depression, or health status (Ta-
ble 2). Of those intensifying therapy with
insulin,6%hadatleastonehypoglycemic
event compared with 2% of those who
intensiﬁedtherapywithoralmedications.
Of those who intensiﬁed therapy with in-
sulin,19%achievedA1C7%compared
with 22% of those who intensiﬁed ther-
apy with oral medications (Table 2).
In adjusted analyses of those who in-
tensiﬁed therapy with either oral antihy-
perglycemicmedicationsorinsulin,black
race/ethnicity versus white, lower income
($15,000 vs. $75,000), higher base-
line A1C, and greater number of fol-
low-up visits to the PCP were associated
with a decrease in A1C from baseline to
follow-up (Table 3). Younger age (50
vs. 70 years and 50–70 vs. 70 years)
andreceivingdiabetescarefromanendo-
crinologist were associated with an in-
crease in A1C from baseline to follow-up
(Table 3).
CONCLUSIONS — We examined
the characteristics of managed care pa-
tientswithsuboptimallycontrolledtype2
diabetes who intensiﬁed antihyperglyce-
mictherapyoveran18-monthperiodand
the associated changes in glycemic con-
trol, weight, anxiety/depression, quality
of life, and hypoglycemia. We found that
48% of patients using diet/exercise ther-
apyaloneororalantihyperglycemicmed-
ications and with baseline A1C 7.2%
intensiﬁed therapy with either oral medi-
cations or insulin: 70% added one or
more classes of oral antihyperglycemic
medications and 30% began insulin. Pa-
tients who intensiﬁed therapy with oral
antihyperglycemic medications or insulin
were younger and had higher baseline
A1C than those who remained with the
same therapy.
Comparedwiththosewhointensiﬁed
therapy with oral antihyperglycemic
medications, those who intensiﬁed ther-
apywithinsulinhadhigherbaselineA1C,
higher Charlson index, and a greater
number of follow-up visits to the PCP.
Compared with patients who remained
with the same therapy, those who inten-
siﬁed therapy experienced a reduction in
A1C, a slight increase in weight, no sig-
niﬁcant change in anxiety/depression or
health status, and no signiﬁcant increase
in hypoglycemia. Despite initiating oral
medications or insulin, only about one-
ﬁfth of patients achieved an A1C 7%.
Karteretal.(9)studiedpatientswithA1C
8% who initiated new diabetes thera-
piesandfoundthat18%achievedanA1C
7% in one of the populations (Kaiser
Permanente) included in the present
study. Our ﬁndings are consistent with a
subsequent study by Karter et al. (10) in
the same population that reported a re-
duction in A1C with treatment intensiﬁ-
cation. In that study, A1C reduction was
similar across classes of antihyperglyce-
mic medications (sulfonylurea, met-
formin, thiazolidinedione, or insulin),
andtreatmenteffectsdidnotdifferbyage,
race,diabetesduration,obesity,orlevelof
renal function.
We also examined the characteristics
of patients whose A1C levels improved
after intensiﬁcation of antihyperglycemic
McEwen and Associates
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intensiﬁed therapy, improvement in A1C
was associated with higher baseline A1C,
older age, black race/ethnicity, lower in-
come, and greater number of visits to the
PCP. Rodondi et al. (7) showed that in a
routine clinical setting, minorities are less
likely to get appropriate intensiﬁcation of
therapy. Recently, Schmittdiel et al. (11)
demonstratedthatclinicalinertiaisasim-
portant a barrier to improved glycemic
control as is medication nonadherence.
The UK Prospective Diabetes Study (UK-
PDS), in the context of a clinical trial,
demonstrated that Afro-Caribbean pa-
tients and Asians of Indian origin were
as likely as Caucasians to achieve good
A1C control (12). The Action in Diabetes
and Vascular Disease: Preterax and Dia-
micronModiﬁedReleaseControlledEval-
uation (ADVANCE) (13) and Action to
Table1—Characteristicsofpatientswithtype2diabetestreatedwithdiet/exerciseororalmedicationsatbaselineandwithA1C>7.2:TRIAD
2000–2002
Total
population
Stayed the
same
Intensiﬁed
therapy P
Intensiﬁed with oral
medication(s)
Intensiﬁed with
insulin P
n 1,093 573 520 362 158
Age 59  12 61  12 58  12 0.0001 58  12 57  12 0.374
Male sex 556 (51) 298 (52) 258 (50) 0.430 191 (53) 67 (42) 0.030
Race/ethnicity 0.665 0.584
Hispanic 184 (17) 102 (18) 82 (16) 57 (16) 25 (16)
Black 116 (11) 65 (11) 51 (10) 32 (9) 19 (12)
White 367 (34) 186 (32) 181 (35) 124 (34) 57 (36)
Asian/Paciﬁc Islander 305 (28) 161 (28) 144 (28) 107 (30) 37 (23)
Other 121 (11) 59 (10) 62 (12) 42 (12) 20 (13)
Income 0.365 0.183
15,000 USD 212 (19) 113 (20) 99 (19) 61 (17) 38 (24)
15,000–40,000 USD 368 (34) 205 (36) 163 (31) 112 (31) 51 (32)
40,000–75,000 USD 309 (28) 154 (27) 155 (30) 112 (31) 43 (27)
$75,000 204 (19) 101 (18) 103 (20) 77 (21) 26 (16)
Education 0.910 0.129
Some high school or less 180 (16) 95 (17) 85 (16) 57 (16) 28 (18)
High school graduate 308 (28) 157 (27) 151 (29) 98 (27) 53 (34)
Some college 376 (34) 202 (35) 174 (33) 121 (33) 53 (34)
4 year college 229 (21) 119 (21) 110 (21) 86 (24) 24 (15)
Diabetes duration (years) 11  10 11  10 11  9 0.787 9.7  9.2 12.6  9.6 0.001
Baseline A1C 8.9  1.5 8.7  1.4 9.1  1.5 0.0001 9.0  1.53 9.5  1.5 0.002
Charlson index 2.1  1.5 2.2  1.4 2.2  1.6 0.920 2.04  1.66 2.43  1.54 0.011
Baseline weight (pounds) 192  49 188  48 196  49 0.008 193  47 201  54 0.106
Baseline BMI (kg/m
2) 31.0  7.1 30.5  7.0 31.4  7.2 0.037 30.9  7.0 32.5  7.5 0.021
Baseline EQ-5D 0.83  0.17 0.84  0.15 0.82  0.18 0.030 0.83  0.17 0.78  21 0.019
Baseline anxiety/depression 0.030 0.082
None 725 (72) 394 (75) 331 (69) 239 (72) 92 (63)
Moderate 250 (25) 122 (23) 128 (27) 83 (25) 45 (31)
Extreme 28 (3) 9 (2) 19 (4) 10 (3) 9 (6)
Smoking 181 (17) 85 (15) 96 (18) 0.107
Diabetes care provided by an
endocrinologist
79 (7) 40 (7) 39 (8) 0.741 24 (7) 15 (10) 0.254
Provider communication 0.747 0.651
4–7 (poor) 77 (8) 37 (8) 40 (9) 25 (8) 15 (11)
8–11 354 (38) 187 (39) 167 (37) 117 (38) 50 (35)
12 (good) 503 (54) 260 (54) 243 (54) 167 (54) 76 (54)
Number of PCP visits 5.5  3.6 5.2  3.5 5.8  3.7 0.018 5.8  3.5 7.2  4.1 0.002
Hospitalized 201 (18) 102 (18) 99 (19) 0.598 55 (15) 44 (28) 0.001
New onset cardiovascular disease 66 (6) 33 (6) 33 (6) 0.684 18 (5) 15 (10) 0.152
New onset retinopathy 124 (11) 64 (11) 60 (12) 0.848 35 (10) 25 (16) 0.043
New onset nephropathy 91 (8) 38 (7) 53 (10) 0.033 27 (7) 26 (16) 0.002
New onset neuropathy 112 (10) 61 (11) 51 (10) 0.648 36 (10) 15 (10) 0.874
New onset of any complication 332 (30) 172 (30) 160 (31) 0.787 94 (26) 66 (42) 0.0003
Dry mouth 309 (30) 163 (30) 146 (29) 0.757 97 (28) 49 (31) 0.452
Excessive thirst 294 (29) 157 (29) 137 (28) 0.668 98 (29) 39 (26) 0.524
Nocturia 513 (48) 279 (50) 234 (46) 0.220 166 (47) 68 (43) 0.406
Data are means  SD or n (%). n  1,093. PCP, primary care physician.
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(ACCORD) (14) studies have similarly
demonstrated that older individuals
(aged 65 years) and minorities are as
likely to achieve glycemic goals as
younger individuals and white individu-
als and that with improvement in A1C
there is equal improvement in outcomes
(13,14). Our study suggests that if treat-
ment is intensiﬁed, outcomes are better,
especially in elderly, minority, and lower
income groups. This ﬁnding highlights
the need for providers to overcome clini-
cal inertia in routine clinical practice.
In light of the ACCORD study, which
randomly assigned patients to an A1C
goal of 6.0 or 7.0–7.9% and found harm
associated with intensive glucose lower-
ing (14), glycemic goals need to be reas-
sessed. The UKPDS supports an A1C goal
of 7.0% for most patients with type 2
diabetes, although this goal may be inap-
propriate for individuals with multiple
comorbidities or poor functional status
(15). The American Geriatric Society rec-
ommends that glycemic goals be estab-
lished on the basis of patient preferences,
life expectancy, and comorbidities and
that the decision to intensify therapy
needs to be modiﬁed by the patients’ ex-
pectations (16).
Therewereanumberoflimitationsto
our study. First, we assessed antihyper-
glycemic treatment using only pharmacy
claims and utilization data. Because pa-
tients without pharmacy beneﬁts lack ﬁ-
nancial incentives to use health plan
pharmacies, some utilization data may
not be captured. We minimized this po-
tential bias by excluding from the analy-
ses anyone with no pharmacy claims or
utilization at either baseline or follow-up.
Second, we deﬁned intensiﬁcation of
therapy on the basis of adding classes of
medications and not by increasing the
dose of the same oral antidiabetic medi-
cation. As a result, the observed differ-
ences between subjects with intensiﬁed
versusnonintensiﬁedtherapyarelikelyto
be conservative. Third, we did not assess
medication adherence, which may have
resulted in a conservative bias if patients
ﬁlled prescriptions for new therapies but
failed to take the medications. Moreover,
a portion of patients may have been pre-
scribed new therapies but never picked
themupfromthepharmacy(i.e.,primary
nonadherence). Reliance on pharmacy
utilization data and claims precludes
identifying this less common type of non-
adherence (5% of new prescriptions), a
patient factor that is typically misclassi-
ﬁed as clinical inertia. Fourth, we were
unable to evaluate baseline status and
synchronize the time of initiation of new
therapies (i.e., new user cohort design)
(17).Althoughourdesignhadalessstrin-
gent data collection schedule, our ﬁnd-
ings should simulate observations made
in usual care, e.g., during primary care
visits. Fifth, many of our analyses were
descriptive and not adjusted for potential
confounders. Finally, our patients were
all enrolled in managed care health plans.
Consequently,theresultsmaynotbegen-
eralizable to uninsured patients with dia-
betes or those in other systems of care.
Failure to appropriately intensify ther-
apy, or clinical inertia, remains an impor-
tant barrier to optimal glycemic control.
Table 2—Unadjusted outcomes associated with intensiﬁcation of therapy for patients with
type 2 diabetes treated with diet/exercise or oral medications at baseline and with A1C >7.2:
TRIAD 2000–2002
Change from 2000 to 2002
Stay the
same
Intensify with oral
medication or
insulin
Intensify with oral
medication(s)
Intensify
with insulin
A1C (%) 0.36 0.84* 0.73 1.10†
Weight (pounds) 3.20 0.06* 0.47 1.22
Increase in anxiety/depression 9 8 8 7
Decrease in health status 33 36 35 39
Met goal A1C of 7% 17 21 22 19
At least one hypoglycemic
event
33 2 6
†
Data are percent unless otherwise indicated. n  1,093. *P  0.01 vs. stay the same. †P  0.05 vs. intensify
with oral medication.
Table 3—Characteristics associated with a change in A1C from baseline to follow-up in
patientswithtype2diabetestreatedwithdiet/exerciseororalmedicationsatbaselineandwith
A1C >7.2: TRIAD 2000–2002
Estimate P
Age-group (referent  70 years)
50 years 0.73 0.004
50–70 years 0.31 0.021
Sex (referent  male) 0.02 0.878
Race/ethnicity (referent  white)
Hispanic 0.23 0.313
Black 0.48 0.031
Asian/Paciﬁc Islander 0.16 0.247
Other 0.30 0.109
Income (referent  75,000 USD)
15,000 USD 0.65 0.005
15,000–40,000 USD 0.26 0.103
40,000–75,000 USD 0.05 0.799
Education (referent  4 year college)
Some high school or less 0.27 0.347
High school graduate 0.1 0.543
Some college 0.16 0.396
Baseline A1C 0.58 0.0001
Intensiﬁcation with insulin (referent  oral medication) 0.03 0.820
BMI (kg/m
2) 0.011 0.345
Charlson index 0.04 0.205
Diabetes care provided by an endocrinologist 0.44 0.011
Number of PCP visits 0.05 0.004
Hospitalized 0.26 0.055
New onset of any complication 0.18 0.185
n  520. Results are adjusted for all variables presented in the table.
McEwen and Associates
DIABETES CARE, VOLUME 32, NUMBER 6, JUNE 2009 975Although it is important to individualize
treatment, our study clearly indicates that
intensifying therapy lowers A1C without
substantial weight gain, worsening anxi-
ety/depression or health status, or hypo-
glycemia. Intensiﬁcation is especially
effectiveinimprovingglycemiccontrolin
elderly, lower income, and minority pa-
tients, groups who may be less likely to
have therapy intensiﬁed and who experi-
ence a disproportionate burden of diabe-
tes and its complications (18–21). More
research is needed to deﬁne and compare
the glucose-lowering and side effect pro-
ﬁles of individual therapeutic medica-
tions, and careful consideration is needed
regarding the risks of intensiﬁcation in el-
derly patients. Interventions should be
implemented to overcome clinical inertia
when patients might beneﬁt from treat-
ment intensiﬁcation and improved glyce-
mic control.
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